Filed Pursuant to Rule 424(b)(3)
Registration No. 333-257731
PROSPECTUS SUPPLEMENT NO. 7
(to Prospectus dated
August 6, 2021)
JANUS INTERNATIONAL GROUP, INC.
Up to 114,045,400 Shares of Common Stock
Up to 10,150,000 Warrants
Up to 10,150,000 Shares of Common Stock Underlying Warrants
This prospectus supplement supplements the prospectus dated August 6, 2021 (the Prospectus), which forms a part of our registration statement
on Form S-1 (No. 333-257731). This prospectus supplement is being filed to update and supplement the information in the Prospectus with the information contained in our
current report on Form 8-K, filed with the Securities and Exchange Commission on March 15, 2022 (the Current Report). Accordingly, we have attached the Current Report to this prospectus
supplement.
The Prospectus and this prospectus supplement relate to resale from time to time of up to 114,045,400 shares of our common stock, par value
$0.0001 per share (the Common Stock), 10,150,000 warrants to purchase Common Stock of the Company (the Warrants) and 10,150,000 shares of Common Stock issuable upon exercise of the Warrants by the selling securityholders
named in the Prospectus (each a Selling Securityholder and collectively, the Selling Securityholders). The Common Stock may be offered from time to time up to specified limits by one or more of the Selling Securityholders
identified in the Prospectus or in any supplement to the Prospectus. See the sections of the Prospectus entitled Selling Securityholders and Plan of Distribution.
Our Common Stock is listed on the New York Stock Exchange (NYSE) under the symbol JBI. On March 11, 2022, the closing sale price
of our Common Stock was $9.30. Our Warrants were listed on NYSE under the symbol JBI WS until November 11, 2021. On November 11, 2021, the closing sale price of our Warrants was $3.80. As of 5:00 p.m., Eastern Time, on
November 12, 2021, all of our outstanding Warrants have been redeemed.
This prospectus supplement updates and supplements the information in the
Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus
and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.
Investing in our Common Stock involves risks that are described in the Risk Factors section beginning on page 7 of the
Prospectus and under similar headings in any further amendments or supplements to the Prospectus.
Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is March 15, 2022.